Clinical Trial Update: Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating PCSK9 inhibitors for efficacy and safety in patients with heterozygous familial hypercholesterolemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heterozygous Familial Hypercholesterolemia

Snippet

Sponsor: Shenzhen People's Hospital | Conditions: Efficacy and Safety, Heterozygous Familial Hypercholesterolemia | Phase 3 | Status: UNKNOWN